MIRAQULES
Miraqules is a biomedical startup dedicated to developing fast-acting anti-bleeding solutions and biomaterial-based wound management products. Founded in 2018, the company aims to replace conventional wound management methods with innovative, affordable, point-of-care solutions that can save lives in emergency bleeding situations. Their flagship products, StopBleed® Powder and StopBleed® Pro, are designed for rapid hemostasis and targeted delivery, respectively. The company is led by CEO and Co-Founder Sabir Hossain, who specializes in biomaterial-based wound healing products. Miraqules has achieved numerous awards, patents, and funding milestones, and is committed to revolutionizing wound care technology.
Industries
Nr. of Employees
small (1-50)
MIRAQULES
16, Bhuvanappa Layout, Tavarekere Main Rd, Bengaluru, Karnataka 560029
Products
StopBleed Powder
A powder-form biomaterial hemostat formulated to conform to irregular and complex wounds; intended to concentrate clotting factors, prevent infection, and stop bleeding rapidly (manufacturer claims ~5x faster than comparable products).
StopBleed Pro (pellet with pre-filled applicator)
A pellet-form hemostat delivered via a pre-filled applicator designed for targeted delivery into narrow-entry wounds (e.g., penetrating trauma); intended for quick application without prior training.
StopBleed Powder
A powder-form biomaterial hemostat formulated to conform to irregular and complex wounds; intended to concentrate clotting factors, prevent infection, and stop bleeding rapidly (manufacturer claims ~5x faster than comparable products).
StopBleed Pro (pellet with pre-filled applicator)
A pellet-form hemostat delivered via a pre-filled applicator designed for targeted delivery into narrow-entry wounds (e.g., penetrating trauma); intended for quick application without prior training.
Expertise Areas
- Biomaterial-based hemostat development
- Wound management biomaterials
- Preclinical and large-animal safety testing
- Manufacturing scale-up and pilot production
Key Technologies
- Porous fibrous matrix biomaterials
- Room-temperature Coulomb-interaction fabrication
- High-absorbency hemostatic matrices
- Powder and pellet hemostat formulations
News & Updates
Q2-2018 Milestone
Established initial proof of concept.
First Patent Filed
Filed the company's first patent.
Received Government Grant
Received a grant from the Government of India.
Q2-2019 Milestone
Completed prototyping and filed second patent.
Q4-2019 Milestone
Made PCT applications for patents.
Q2-2020 Milestone
Completed preclinical trials and released a functioning prototype.
Q2-2018 Milestone
Established initial proof of concept.
First Patent Filed
Filed the company's first patent.
Received Government Grant
Received a grant from the Government of India.
Q2-2019 Milestone
Completed prototyping and filed second patent.
Q4-2019 Milestone
Made PCT applications for patents.
Q2-2020 Milestone
Completed preclinical trials and released a functioning prototype.